EP Patent

EP1548008A4 — COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION

Assigned to Kirin Pharma KK · Expires 2008-08-06 · 18y expired

What this patent protects

A compound represented by the following formula (I); a pharmaceutically acceptable salt of the compound; and a solvate thereof. [In the formula (I), X represents CH or N; Z represents -O-, -NH-, or -C(=O)-; R and R' each represents hydrogen, hydroxy, halogeno, optionally substitu…

USPTO Abstract

A compound represented by the following formula (I); a pharmaceutically acceptable salt of the compound; and a solvate thereof. [In the formula (I), X represents CH or N; Z represents -O-, -NH-, or -C(=O)-; R and R' each represents hydrogen, hydroxy, halogeno, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group.] The compounds have excellent TGFß inhibitory activity.

Drugs covered by this patent

Patent Metadata

Patent number
EP1548008A4
Jurisdiction
EP
Classification
—
Expires
2008-08-06
Drug substance claim
No
Drug product claim
No
Assignee
Kirin Pharma KK
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.